SCHEMBL5217102

SCHEMBL5217102

CCOC(=O)c1ccc(C)c(-n2cc(-c3nc4ccccc4o3)cn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
NPC1 O15118 4/20 0.47
KDM4E B2RXH2 4/20 0.47
HSD17B10 Q99714 4/20 0.47
ALDH1A1 P00352 4/20 0.47
RAB9A P51151 3/20 0.47
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TP53 P04637 3/20 0.45
ABL1 P00519 2/20 0.43
BCR P11274 2/20 0.43
KMT2A Q03164 2/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40
PKM P14618 1/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216868 0.86 ALOX15 (0.48) MAPTNPC1KDM4EHSD17B10ALDH1A1
SCHEMBL5217843 0.81 NPC1 (0.60) MAPTNPC1KDM4EALDH1A1RAB9A
SCHEMBL5218434 0.81 NPC1 (0.47) MAPTNPC1KDM4EALDH1A1RAB9A
SCHEMBL5216455 0.79 NPC1 (0.42) MAPTNPC1KDM4EHSD17B10ALDH1A1
SCHEMBL593327 0.77 KDM4E (0.58) MAPTNPC1KDM4EHSD17B10ALDH1A1
SCHEMBL13887410 0.76 CA12 (0.46) MAPTNPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL17125410 0.75 MAPT (0.69) MAPTNPC1KDM4EHSD17B10ALDH1A1
SCHEMBL5218794 0.74 NPC1 (0.48) MAPTNPC1KDM4EHSD17B10ALDH1A1
SCHEMBL4013954 0.74 CA12 (0.43) MAPTNPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL13848965 0.74 CA12 (0.43) MAPTNPC1ALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C MAPT 2547/4885NPC1 4205/4885KDM4E 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.